secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001640334-23-000791
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria Bioscience shareholders reelect all 6 director nominees and approve all proposals at annual meeting
--------------------------------------------------------------------------------

- All six director nominees elected: Bunka (96.5%), Docherty (96.3%), Baxter (74.3%), McKechnie (95.7%), Reese (96.2%), Turkel (97.6%).
- Stock option repricing approved with 68.9% of votes cast (1,529,271 for; 677,686 against).
- Amendment to Incentive Equity Plan (max shares) approved with 88.6%; evergreen formula addition approved with 63.1%.
- Appointment of Malone Bailey LLP as auditors ratified with 96.4% (3,249,199 for).
- Ratification of directors' past actions approved with 90.4%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033423000791/0001640334-23-000791-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033423000791/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-23-000791

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer